← Back to Search

Loop Diuretic

High-Dose Diuretics for Heart Failure

Phase 2

Waitlist Available

Led By Yogesh Reddy, M.B.B.S

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of decompensated heart failure receiving intravenous diuretics

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 hours

Awards & highlights

Study Summary

This trial will compare two types of diuretics to treat heart failure. It will look at safety and effectiveness over 24 hours.

Who is the study for?

This trial is for adults with decompensated heart failure already on IV diuretics. It's not for those under 40 kg, unable to consent, pregnant/breastfeeding, with complex heart issues or severe kidney disease, recent serious arrhythmias or heart attacks, on home inotrope meds, allergic to the study drugs, or critically unstable.Check my eligibility

What is being tested?

The study tests if ultrahigh doses of diuretics (Bumetanide and Furosemide) are safe and more effective than standard doses in treating patients with decompensated heart failure over a day.See study design

What are the potential side effects?

Potential side effects may include dehydration, electrolyte imbalances like low potassium or sodium levels which can cause weakness or confusion; kidney function changes; and possibly blood pressure drops.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have severe heart failure and am receiving IV diuretics.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Urine Output

Secondary outcome measures

Change in Body Weight

Change in Cardiac Output

Change in E/e'

+10 more

Side effects data

From 2019 Phase 2 trial • 34 Patients • NCT03923933

69%

Creatinine Increase

25%

hyperuricemia

13%

Hyponatremia

13%

hypokalemia

Major adverse cardiovascular events

100%

80%

60%

40%

20%

Study treatment Arm

Placebo

Treatment Grup

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Ultra-high dose diuretic groupExperimental Treatment1 Intervention

Subjects with decompensated heart failure requiring hospitalization will receive IV bumetanide.

Group II: Standard dose diuretic groupActive Control1 Intervention

Subjects with decompensated heart failure requiring hospitalization will receive IV furosemide.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Bumetanide

2010

Completed Phase 2

~260

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,207 Previous Clinical Trials

3,767,120 Total Patients Enrolled

72 Trials studying Heart Failure

1,022,008 Patients Enrolled for Heart Failure

Yogesh Reddy, M.B.B.SPrincipal InvestigatorMayo Clinic

1 Previous Clinical Trials

40 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you detail the potential risks of employing ultra-high dosage diuretics?

"Despite not having any clinical data confirming its efficacy, our team at Power assigned an intermediate score of 2 to ultra-high dose diuretics in terms of safety due to existing evidence backing their security."

Answered by AI

Are there any open slots available for participation in this medical experiment?

"According to the information posted on clinicaltrials.gov, this particular trial is not actively enrolling any new patients at present. The medical study was first advertised on October 1st 2023 and last updated in September of that same year. Despite its lack of recruitment status, there are 755 other trials currently welcoming candidates into their studies."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of Ultra High Dose Diuretics to Treat Heart Failure

Yogesh Reddy 2023. "A Study of Ultra High Dose Diuretics to Treat Heart Failure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06036914.